Assignee
AXOVANT SCIENCES GMBH
CH·5 granted patents·12 pending applications·11 citations·filing 2015–2020
Top patents by PatentIndex Score
17 records- 0188US10034859B2Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative diseaseAXOVANT SCIENCES GMBH·Filed 2016·Granted Jul 31, 2018·4 cites·50 claims
- 0284US11304932B2Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative diseaseAXOVANT SCIENCES GMBH·Filed 2020·Granted Apr 19, 2022·1 cites·28 claims
- 0384US10022355B2Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorderAXOVANT SCIENCES GMBH·Filed 2016·Granted Jul 17, 2018·5 cites·68 claims
- 0464US9808455B2Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinolineAXOVANT SCIENCES GMBH·Filed 2015·Granted Nov 7, 2017·1 cites·14 claims
- 0563US2019315736A1Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide Hydrochloride MonohydrateAXOVANT SCIENCES GMBH·Filed 2018·Application pending·0 cites
- 0662US2019160043A1Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of rem sleep behavior disorderAXOVANT SCIENCES GMBH·Filed 2018·Application pending·0 cites
- 0762US2019151287A1Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative diseaseAXOVANT SCIENCES GMBH·Filed 2018·Application pending·0 cites
- 0860US2020397754A1Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of rem sleep behavior disorderAXOVANT SCIENCES GMBH·Filed 2020·Application pending·0 cites
- 0957US2021128528A1Use of 5ht2a inverse agonists for treating psychosisAXOVANT SCIENCES GMBH·Filed 2020·Application pending·0 cites
- 1052US2019350927A1Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinolineAXOVANT SCIENCES GMBH·Filed 2018·Application pending·0 cites
- 1151US2018214431A1Methods of Maintaining, Treating or Improving Cognitive FunctionAXOVANT SCIENCES GMBH·Filed 2017·Application pending·0 cites
- 1250US2019046506A1Use of 5ht2a inverse agonists for treating psychosisAXOVANT SCIENCES GMBH·Filed 2018·Application pending·0 cites
- 1349US2018085367A1Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinolineAXOVANT SCIENCES GMBH·Filed 2017·Application pending·0 cites
- 1444US2019111052A1Methods of treating a neurodegenerative diseaseAXOVANT SCIENCES GMBH·Filed 2018·Application pending·0 cites
- 1542US2017246163A1Methods of improving balance, gait or both in patients with neurological diseaseAXOVANT SCIENCES GMBH·Filed 2017·Application pending·0 cites
- 1635US10183938B2Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptorsAXOVANT SCIENCES GMBH·Filed 2015·Granted Jan 22, 2019·0 cites·15 claims
- 1733US2018042922A1Compositions and methods of treating a neurodegenerative diseaseAXOVANT SCIENCES GMBH·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when AXOVANT SCIENCES GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →